Evaluation of Dosing Interval of Higher Doses of Ranibizumab

Conditions

ranibizumab — DRUG
Arm A: 0.5 mg ranibizumab on day 0 with retreatment based on defined criteria not to occur sooner than every 28 days Arm B: 1.0 mg ranibizumab on day 0 with retreatment based on defined criteria not to occur sooner than every 28 days Third Arm 2.0mg Arm with retreatment based on defined criteria not to occur sooner than every 28 days

Evaluation of Dosing Interval of Higher Doses of Ranibizumab for patients with wet age-related macular degeneration (AMD).

Active Comparator: 0.5mg ranibizumab
Subjects will be treated with 0.5mg ranibizumab at the Day 0 visit and the as needed based on defined retreatment criteria no sooner than every 28 days since last treatment.
Active Comparator: 1.0mg ranibizumab
Subjects will be treated with 1.0mg ranibizumab at the Day 0 visit and the as needed based on defined retreatment criteria no sooner than every 28 days since last treatment.
Active Comparator: 2.0mg ranibizumab
Subjects will be treated with 2.0 mg ranibizumab at the Day 0 visit and the as needed based on defined retreatment criteria no sooner than every 28 days since last treatment.

Safety - Presence of intraocular inflammation following intravitreal ranibizumab injection [ Time Frame: 24 months ]

Facility	City	State	ZIP	Site coordinators
Tennessee Retina, P.C.	Nashville	Tennessee	37203	-

By condition

By specialty

By research site